Skip to main content

Table 1 Baseline characteristics of the studies included

From: Comparison of denosumab and zoledronic acid for the treatment of solid tumors and multiple myeloma with bone metastasis: a systematic review and meta-analysis based on randomized controlled trials

Study Cancer type Interventions Follow-up (mon) N (denosumab/ZA) Primary endpoint
Stopeck et al. (2010) [22] Breast cancer Denosumab 120 mg SC versus ZA 4 mg IV 33 1026/1020 Time to first SRE
Fizazi et al. (2011) [21] Prostate cancer Denosumab 120 mg SC versus ZA 4 mg IV 40.5 943/945 Time to first SRE
Henry et al. (2014) [23] Various solid tumors Denosumab 120 mg SC versus ZA 4 mg IV 34 800/797 Time to first SRE
Raje et al. (2018) [20] Multiple myeloma Denosumab 120 mg SC versus ZA 4 mg IV 50 859/859 Time to first SRE